Type of ward (reference: Medical)
|
ICU
|
0.94
|
0.83
|
0.07
|
0.005
|
0.01–0.46
|
Surgical
|
0.95
|
0.81
|
0.66
|
0.19
|
0.35–1.23
|
Ward size in 2013, per increase of 50 beds
|
0.90
|
0.14
|
0.79
|
0.02
|
0.64–0.97
|
Type of HCF (reference: General hospital)
|
University hospital
|
0.42
|
0.35
|
0.28
|
0.25
|
0.03–2.39
|
Private hospital
|
1.06
|
0.85
|
0.66
|
0.28
|
0.31–1.40
|
Cancer centre
|
0.37
|
0.29
|
0.09
|
0.04
|
0.01–0.88
|
Local hospital
|
2.33
|
0.18
|
1.19
|
0.83
|
0.25–5.54
|
Rehabilitation and long-term care facility
|
0.38
|
0.50
|
0.24
|
0.40
|
0.01–6.59
|
Military hospital
|
0.43
|
0.34
|
0.18
|
0.09
|
0.02–1.28
|
Geographical area (reference: South-east)
|
North
|
1.42
|
0.42
|
2.33
|
0.09
|
0.88–6.16
|
West
|
1.15
|
0.80
|
1.09
|
0.90
|
0.30–3.94
|
East
|
1.93
|
0.15
|
3.11
|
0.03
|
1.10–8.77
|
South-west
|
1.78
|
0.17
|
1.57
|
0.36
|
0.60–4.12
|
Antibiotic use, DDDs per 1000 patients-days
|
Initial CBP useb
|
1.01
|
0.01
|
0.97
|
0.08
|
0.95–1.00
|
Initial prescribing profile of CBPsc
|
1.22
|
0.002
|
3.16
|
< 0.001
|
1.88–5.34
|
Initial 3GC useb
|
1.00
|
0.79
| | | |
Initial prescribing profile of 3GCsc
|
0.97
|
0.16
|
0.89
|
0.002
|
0.83–0.96
|
Reduction in 3GC used
|
1.34
|
0.23
| | | |
Initial FQ useb
|
1.00
|
0.25
| | | |
Initial prescribing profile of FQsc
|
1.02
|
0.29
| | | |
Reduction in FQ used
|
2.21
|
0.004
|
2.3
|
0.02
|
1.17–4.53
|
Initial AG useb
|
1.00
|
0.50
| | | |
Initial prescribing profile of AGsc
|
0.97
|
0.44
| | | |
Reduction in AG used
|
1.56
|
0.06
|
1.13
|
0.67
|
0.65–1.96
|
Initial AP ± BLI useb
|
1.00
|
0.83
| | | |
Initial prescribing profile of AP±BLIsc
|
1.00
|
0.99
| | | |
Reduction in AP ± BLI used
|
1.10
|
0.68
| | | |
Initial Imidazole useb
|
1.00
|
0.98
| | | |
Initial prescribing profile of imidazolesc
|
0.97
|
0.45
| | | |
Reduction in imidazole used
|
1.65
|
0.03
|
1.50
|
0.15
|
0.87–2.59
|
Initial GP useb
|
1.00
|
0.95
| | | |
Initial prescribing profile of GPsc
|
0.97
|
0.61
| | | |
Reduction in GP used
|
1.83
|
0.01
|
1.98
|
0.02
|
1.13–3.45
|
Initial TZP useb
|
1.00
|
0.99
| | | |
Initial prescribing profile of TZPc
|
0.95
|
0.33
| | | |
Reduction in TZP used
|
4.24
|
< 0.001
|
4.02
|
< 0.001
|
1.99–8.14
|
Initial use of other alternatives to CBPsb
|
1.00
|
0.88
| | | |
Initial prescribing profile of other alternatives to CBPsc
|
1.31
|
0.25
| | | |
Reduction in the use of other alternatives to CBPsd
|
1.07
|
0.79
| | | |
Initial overall antibiotic useb
|
1.00
|
0.72
|
1.00
|
0.97
|
0.99–1.01
|
Reduction in the overall antibiotic used
|
2.02
|
0.003
|
1.38
|
0.29
|
0.76–2.51
|
Region with high ESBL-PE incidence rate in acute care settingse
|
0.65
|
0.12
|
0.40
|
0.01
|
0.19–0.82
|